...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.
【24h】

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.

机译:BMS-207147针对来自北美和拉丁美洲SENTRY抗菌监测计划的600多种当代念珠菌临床分离株的体外活性。

获取原文
获取原文并翻译 | 示例
           

摘要

We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole against 613 clinical bloodstream isolates of Candida spp. collected from SENTRY participating hospitals during 1997 and 1998. Overall, BMS-207147 was the most active azole against all Candida spp. While both BMS-207147 and itraconazole displayed a stepwise decrease in activity against isolates for which the fluconazole MICs were elevated, BMS-207147 had two- to fourfold greater activity than itraconazole both against Candida spp. that were dose-dependently fluconazole susceptible and against those that were fluconazole resistant.
机译:我们比较了正在研究的三唑BMS-207147与伊曲康唑和氟康唑对613种念珠菌临床血液分离株的体外活性。在1997年至1998年期间,这些药物是从SENTRY参与医院收集的。总体而言,BMS-207147是对抗所有假丝酵母菌活性最强的唑。虽然BMS-207147和伊曲康唑对氟康唑MICs升高的分离株的活性均呈逐步降低的趋势,但BMS-207147的抗假丝酵母活性均比伊曲康唑高2-4倍。氟康唑对剂量敏感,对氟康唑耐药。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号